一品红(300723) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 reached ¥716,001,917.53, representing a 38.84% increase compared to ¥515,706,771.99 in the same period last year[11] - Net profit attributable to shareholders was ¥111,105,560.23, up 39.24% from ¥79,793,126.38 year-on-year[11] - The net profit after deducting non-recurring gains and losses was ¥93,197,609.34, reflecting a 30.96% increase from ¥71,163,480.42 in the previous year[11] - The company achieved total operating revenue of ¥716,001,917.53, a year-on-year increase of 38.84%[37] - Revenue from pharmaceutical manufacturing products reached ¥706,272,400, representing a year-on-year growth of 41.64%[37] - The net profit attributable to shareholders was ¥111,105,600, up 39.24% year-on-year[37] - The net profit for Q1 2023 was CNY 104,375,558.02, compared to CNY 73,697,481.95 in the same period last year, indicating a significant increase of approximately 41.6%[72] - The company's revenue from fees and commissions rose to CNY 609,093,532.39, up from CNY 438,187,253.22, marking a growth of around 39%[72] Cash Flow and Assets - The company's cash flow from operating activities was ¥32,399,255.97, a 15.44% increase compared to ¥28,065,728.53 in Q1 2022[11] - Cash received from other operating activities increased by 49.56% to 40,525,892.06 from 27,097,650.73 in Q1 2022[45] - Cash flow from operating activities for the current period is ¥32,399,255.97, compared to ¥28,065,728.53 in the previous period, indicating a positive trend[63] - Total cash inflow from operating activities is ¥763,000,086.33, an increase from ¥604,375,791.80 in the previous period[63] - The company's cash and cash equivalents increased to CNY 797,920,929.44 from CNY 645,595,752.99, representing a growth of about 23.54%[57] - The total assets at the end of Q1 2023 were ¥4,359,057,480.16, a 6.36% increase from ¥4,098,442,245.37 at the end of the previous year[11] - As of March 31, 2023, the company's total assets amounted to CNY 4,359,057,480.16, an increase from CNY 4,098,442,245.37 at the beginning of the year, reflecting a growth of approximately 6.36%[57] Investments and R&D - R&D expenses increased by 40.53% to ¥48,121,692.21, driven by accelerated investment in ongoing projects[16] - The company invested ¥48,121,700 in R&D, a 40.53% increase compared to the previous period[39] - The company is focusing on enhancing its R&D capabilities through various innovative mechanisms, including independent and collaborative research[67] - The company aims to expand its product pipeline in pediatric medicine, chronic disease treatment, and biological vaccines[67] Liabilities and Equity - In Q1 2023, the total liabilities of Yipinhong Pharmaceutical reached CNY 2,088,424,718.81, an increase from CNY 1,932,641,616.02 in the previous year, reflecting a growth of approximately 8.1%[70] - The total owner's equity increased to CNY 2,270,632,761.35 from CNY 2,165,800,629.35, representing a growth of about 4.8% year-over-year[70] - The total current liabilities amounted to CNY 1,367,721,791.13, compared to CNY 1,208,855,951.44, which is an increase of about 13.1%[70] Market and Product Development - The company achieved a 41% year-on-year growth in pharmaceutical manufacturing sales, contributing significantly to revenue growth[16] - The company has successfully obtained selection qualifications for new products in the eighth batch of national drug centralized procurement, which is expected to enhance market share and sales[13] - The company’s pharmaceutical manufacturing business remains a cornerstone for sustained revenue growth, particularly in children's and chronic disease medications[38] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[73] Other Financial Metrics - The company's effective tax expense increased by 63.47% to ¥22,467,462.35, driven by higher sales revenue and operating profit[44] - Tax refunds received decreased by 64.84% to 7,419,180.18 from 21,099,956.96 in Q1 2022[45] - The basic and diluted earnings per share for the current period are both ¥0.3851, up from ¥0.2766 in the previous period[61] - The net cash flow from investing activities is -¥269,438,376.20, an improvement from -¥539,481,015.88 in the previous period[63] - Cash flow from financing activities shows a net increase of ¥389,364,296.68, compared to ¥334,117,705.69 in the previous period[63]